Kyu-pyo Kim1, Seong Joon Park1, Jeong-Eun Kim1, Yong Sang Hong1, Jae-Lyun Lee1, Kyun-Seop Bae2, Hyunju Cha3, Sool-Ki Kwon3, Seonggu Ro3, JoongMyung Cho3, Tae Won Kim4. 1. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. 2. Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. 3. CrystalGenomics, Inc., Seongnam-si, Gyeonggi-do, Korea. 4. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. twkimmd@amc.seoul.kr.
Abstract
PURPOSE: The aim of the present study was to assess the safety, maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and efficacy of single and multiple doses of intravenous CG200745, a novel histone deacetylase (HDAC) inhibitor, in patients with advanced solid malignancies. EXPERIMENTAL DESIGN: Two to six patients received intravenous CG200745 according to the 2 + 4 dose-escalating method. This first-in-human trial was comprised of two parts: Part 1 was a single ascending dose, and Part 2 was multiple ascending doses weekly for 3 weeks, and then 1 week off. For the first cycle, pharmacokinetic sampling for CG200745 and pharmacodynamic sampling for acetylated histone H4 in peripheral blood mononuclear cells (PBMCs) were performed on day 1 for Part 1 and on days 1 and 15 for Part 2. Examination of acetylated histone H4 in pre- and post-biopsy samples was performed in accessible patients. RESULTS: In all, 28 patients were treated at 13 dose levels (1.8-250 mg/m(2)) and received a total of 71 cycles of CG200745. Hematologic toxicities included grade 3/4 neutropenia (22.2 %) that did not last a week and non-hematologic toxicities included fatigue (22.2 %) and anorexia (16.7 %) that did not exceed grade 2. No dose-limiting toxic effects were noted. Dose proportionality was observed for both the maximum concentration and area under the curve. The elimination half-life was 5.67 ± 2.69 h (mean ± standard deviation). An increase in PBMC acetylated histone H4 was observed at dose levels up to 51 mg/m(2), which plateaued at higher dose levels. At 24 h, 75 % of patients (6/8) showed higher relative acetylation in tumor tissue compared to PBMCs. Although there was no partial or complete response, 57.1 % of patients (16/28) had stable disease that lasted at least 6 weeks. CONCLUSIONS: CG200745 can be safely administered at effective dose levels that inhibit HDAC in PBMCs and tumor tissue. Although MTD was not reached, further escalation was not performed because acetylated histone H4 plateaued at dose levels higher than 51 mg/m(2). Additional phase II trials are recommended at 250 mg/m(2).
PURPOSE: The aim of the present study was to assess the safety, maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and efficacy of single and multiple doses of intravenous CG200745, a novel histone deacetylase (HDAC) inhibitor, in patients with advanced solid malignancies. EXPERIMENTAL DESIGN: Two to six patients received intravenous CG200745 according to the 2 + 4 dose-escalating method. This first-in-human trial was comprised of two parts: Part 1 was a single ascending dose, and Part 2 was multiple ascending doses weekly for 3 weeks, and then 1 week off. For the first cycle, pharmacokinetic sampling for CG200745 and pharmacodynamic sampling for acetylated histone H4 in peripheral blood mononuclear cells (PBMCs) were performed on day 1 for Part 1 and on days 1 and 15 for Part 2. Examination of acetylated histone H4 in pre- and post-biopsy samples was performed in accessible patients. RESULTS: In all, 28 patients were treated at 13 dose levels (1.8-250 mg/m(2)) and received a total of 71 cycles of CG200745. Hematologic toxicities included grade 3/4 neutropenia (22.2 %) that did not last a week and non-hematologic toxicities included fatigue (22.2 %) and anorexia (16.7 %) that did not exceed grade 2. No dose-limiting toxic effects were noted. Dose proportionality was observed for both the maximum concentration and area under the curve. The elimination half-life was 5.67 ± 2.69 h (mean ± standard deviation). An increase in PBMC acetylated histone H4 was observed at dose levels up to 51 mg/m(2), which plateaued at higher dose levels. At 24 h, 75 % of patients (6/8) showed higher relative acetylation in tumor tissue compared to PBMCs. Although there was no partial or complete response, 57.1 % of patients (16/28) had stable disease that lasted at least 6 weeks. CONCLUSIONS:CG200745 can be safely administered at effective dose levels that inhibit HDAC in PBMCs and tumor tissue. Although MTD was not reached, further escalation was not performed because acetylated histone H4 plateaued at dose levels higher than 51 mg/m(2). Additional phase II trials are recommended at 250 mg/m(2).
Authors: Jeffrey S Weber; Laura A Levit; Peter C Adamson; Suanna Bruinooge; Howard A Burris; Michael A Carducci; Adam P Dicker; Mithat Gönen; Stephen M Keefe; Michael A Postow; Michael A Thompson; David M Waterhouse; Susan L Weiner; Lynn M Schuchter Journal: J Clin Oncol Date: 2014-12-15 Impact factor: 44.544
Authors: A Ali; O Bluteau; K Messaoudi; A Palazzo; S Boukour; L Lordier; Y Lecluse; P Rameau; L Kraus-Berthier; A Jacquet-Bescond; H Lelièvre; S Depil; P Dessen; E Solary; H Raslova; W Vainchenker; I Plo; N Debili Journal: Cell Death Dis Date: 2013-07-25 Impact factor: 8.469
Authors: Srividya Subramanian; Susan E Bates; John J Wright; Igor Espinoza-Delgado; Richard L Piekarz Journal: Pharmaceuticals (Basel) Date: 2010-08-26
Authors: Hee Seung Lee; Soo Been Park; Sun A Kim; Sool Ki Kwon; Hyunju Cha; Do Young Lee; Seonggu Ro; Joong Myung Cho; Si Young Song Journal: Sci Rep Date: 2017-01-30 Impact factor: 4.379
Authors: Jung Hyun Jo; Dawoon E Jung; Hee Seung Lee; Soo Been Park; Moon Jae Chung; Jeong Youp Park; Seungmin Bang; Seung Woo Park; Sangsook Cho; Si Young Song Journal: Int J Cancer Date: 2022-06-21 Impact factor: 7.316
Authors: Sang Heon Suh; Hong Sang Choi; Chang Seong Kim; In Jin Kim; Hyunju Cha; Joong Myung Cho; Seong Kwon Ma; Soo Wan Kim; Eun Hui Bae Journal: Int J Mol Sci Date: 2020-02-21 Impact factor: 5.923